reports
DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board ...
DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors Châtillon, France, October 30, 2025 DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), (the “Company” or “DBV”), a clinical-stage biopharmaceutical company, today announced the provisional appointment of a new independent director, Dr. Philina Lee, to its Board of Directors (the “Board”), effective October 30, 2025. Dr. Lee is appointed in replacement of Daniel Soland, subject to the ratification by...
DBV Technologies annonce la nomination de Philina Lee, Ph.D. au sein d...
DBV Technologies annonce la nomination de Philina Lee, Ph.D. au sein de son Conseil d’administration Châtillon, France, 30 octobre 2025 DBV Technologies annonce la nomination de Philina Lee, Ph.D. au sein de son Conseil d’administration DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), (la « Société » ou « DBV »), une société biopharmaceutique au stade clinique, a annoncé ce jour la nomination provisoire d’une nouvelle administratrice indépendante, le Docteur Philina Lee, au sein de son Conseil d’administration (le « Conseil »), effective à compter du 30 octob...
DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientif...
DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting Châtillon, France, October 30, 2025 DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced upcoming participation in the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting, November 6 - 10, in Orlando, Florida. DBV will host a Product Theater titled “Harnessing Immune Plasticity to Alte...
DBV Technologies participe au congrès scientifique annuel de l'ACAAI
DBV Technologies participe au congrès scientifique annuel de l'ACAAI Châtillon, France, le 30 octobre 2025 DBV Technologies participe au congrès scientifique annuel de l'ACAAI DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market : DBVT – CUSIP : 23306J309) une société biopharmaceutique en phase clinique, a annoncé sa participation au congrès scientifique annuel 2025 de l'American College of Allergy, Asthma & Immunology (ACAAI), qui se tiendra du 6 au 10 novembre à Orlando, en Floride. DBV organisera un forum produit intitulé « Harnessing Immune Plasticity to Alt...
DBV Technologies Announces Sale of approximately $30 million of ADSs T...
DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq Châtillon, France, October 29, 2025 DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a clinical-stage biopharmaceutical company, today announced that, pursuant to the Company’s At-The-Market program established on September 5, 2025 (the “ATM Program”), it has agreed to issue and sell new ordinary shares...
DBV Technologies annonce un placement d’ADS pour un montant d’environ ...
DBV Technologies annonce un placement d’ADS pour un montant d’environ 30 millions de Dollars US dans le cadre de son programme At-The-Market (ATM) sur le Nasdaq Châtillon, France, 29 octobre 2025 DBV Technologies annonce un placement d’ADS pour un montant d’environ 30 millions de Dollars US dans le cadre de son programme At-The-Market (ATM) sur le Nasdaq DBV Technologies (la « Société » ou « DBV ») (Euronext : DBV - ISIN : FR0010417345 - Nasdaq Capital Market : DBVT), société biopharmaceutique en phase clinique, annonce ce jour, dans le cadre de son programme de financement dit « At-The-M...
DBV Technologies Reports Third Quarter 2025 Financial Results
DBV Technologies Reports Third Quarter 2025 Financial Results Châtillon, France, October 28, 2025 DBV Technologies Reports Third Quarter 2025 Financial Results DBV closes Q3 2025 with a cash and cash equivalents balance of $69.8 million, taking cash runway into the third quarter of 2026 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company (the "Company"), reported financial results for the third quarter of 2025. The quarterly and nine months unaudited financial statements were approved by the Boar...
DBV Technologies publie ses résultats financiers du troisième trimestr...
DBV Technologies publie ses résultats financiers du troisième trimestre 2025 Châtillon, France, 28 octobre 2025 DBV Technologies publie ses résultats financiers du troisième trimestre 2025 DBV clôture le troisième trimestre 2025 avec un solde de trésorerie & équivalents de trésorerie de 69,8 millions de dollars permettant de financer l’activité jusqu'au troisième trimestre 2026 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), une société biopharmaceutique au stade clinique spécialisée dans les options de traitement des allergies alimen...
Ipsos: Monthly declaration of shares and voting rights - September 202...
Ipsos: Monthly declaration of shares and voting rights - September 2025 October 24, 2025 MONTHLY DISCLOSURE OF THE TOTAL NUMBER OF SHARES AND VOTING RIGHTS Articles L. 233-8 II of the Commercial Code and 223-16 of the General Regulation of the AMF Date Shares Voting rights Theoretical* Exercisable** 30 September 2025 43,203,225 48,979,191 48,925,369 *This number is calculated on the basis of all the shares to which voting rights are attached, including shares which voting rights have been suspended, in accordance with Article 223-11 of the AMF general regulatio...
Ipsos : Déclaration mensuelle d'actions et de droits de vote - Septemb...
Ipsos : Déclaration mensuelle d'actions et de droits de vote - Septembre 2025 24 octobre 2025 PUBLICATION MENSUELLE DU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL ET DU NOMBRE TOTAL DE DROITS DE VOTE Articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’AMF Date Nombre d’actions composant le capital Nombre total de droits de vote théoriques* exerçables** 30 septembre 2025 43 203 225 48 979 191 48 925 369 * Ce nombre est calculé sur la base de l’ensemble des actions auxquelles sont attachés des droits de vote, y compris les actions privées de droit de vote, co...
- Carole Braudeau
GET GETLINK SE
CA CARREFOUR SA
BVI BUREAU VERITAS SA
RNO RENAULT SA
MTX MTU AERO ENGINES AG
ORA ORANGE SA
SW SODEXO SA
FNAC FNAC DARTY SA
KER KERING SA
NEX NEXANS SA
UCG UNICREDIT S.P.A.
REC RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A.
DIGI DIGI COMMUNICATIONS NV
VRLA VERALLIA SAS
AZE AZELIS GROUP NV
SPM SAIPEM S.P.A.
- Emira Sagaama
- Emmanuel Matot
IPS IPSOS
FP TOTAL SE
PEO BANK POLSKA KASA OPIEKI SA
EQNR EQUINOR ASA
GALP GALP ENERGIA SGPS SA CLASS B
ORA ORANGE SA
SSAB A SSAB AB CLASS A
EN BOUYGUES SA
CEN GROUPE CRIT SA
IDL ID LOGISTICS GROUP
SDG SYNERGIE SA
ITP INTERPARFUMS
BLC BASTIDE LE CONFORT MEDICAL SA
PKO PKO BANK POLSKI S.A.
LPE LAURENT-PERRIER SA
GOE GROUPE GORGE SA
FNAC FNAC DARTY SA
ENI ENI S.P.A.
NEX NEXANS SA
ICAD ICADE SA
SPL SANTANDER BANK POLSKA SA
REP REPSOL SA
MIL BANK MILLENNIUM SA
VRNL VERNEUIL PARTICIPATIONS
ERG ERG S.P.A.
CTAC CTAC N.V.
TPS ORANGE POLSKA S.A.
AOF ATOSS SOFTWARE AG
RIEN RIETER HOLDING AG
SESL SES-IMAGOTAG SA
CIE CIE AUTOMOTIVE S.A.
AALB AALBERTS N.V.
CON CONZZETA AG
NVG NAVIGATOR COMPANY SA
INSD VERIMATRIX SA
ALR ALIOR BANK SA
VLTSA VOLTALIA
ECONT ECONOCOM GROUP SE CLASS D
BP. BP P.L.C.
GALE GALENICA AG
VRLA VERALLIA SAS
AZE AZELIS GROUP NV
SHEL SHELL PLC
SPM SAIPEM S.P.A.
4X0 STEYR MOTORS AG
- Emmanuel Matot
- Emmanuel Matot
Good performance in the third quarter in a complex environment
Good performance in the third quarter in a complex environment Good performance in the third quarterin a complex environment Annual organic growth target updated Paris, 23 October 2025 – , one of the world’s leading market research companies, achieved a revenue of €636 million in the third quarter, representing a growth of 7.6%, of which 2.9% organic (up from -1.8% in the first quarter and +0.7% in the second), 8.5% from scope effects mainly related to the acquisitions of The BVA Family and infas, and -3.8% from negative currency effects due to the euro’s appreciation against certain curr...
Bonne performance au troisième trimestre dans un environnement complex...
Bonne performance au troisième trimestre dans un environnement complexe Bonne performance au troisième trimestre dans un environnement complexe Actualisation de l’objectif annuel de croissance organique Paris, 23 octobre 2025 – , l’une des principales sociétés mondiales d’études de marché, a réalisé un chiffre d’affaires de 636 millions d’euros au troisième trimestre, soit une croissance de 7,6 %, dont 2,9 % en organique (en augmentation après -1,8 % au premier trimestre et +0,7 % au deuxième), 8,5 % d’effets de périmètre liés principalement aux acquisitions de The BVA Familly et d’infas,...
DBV Technologies Announces Sale of approximately $30 million of ADSs T...
DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq Châtillon, France, October 6, 2025 DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a clinical-stage biopharmaceutical company, today announced that, pursuant to the Company’s At-The-Market program established on September 5, 2025 (the “ATM Program”), it has agreed to issue and sell new ordinary shares ...
DBV Technologies annonce un placement d’ADS pour un montant d’environ ...
DBV Technologies annonce un placement d’ADS pour un montant d’environ 30 millions de Dollars US dans le cadre de son programme At-The-Market (ATM) sur le Nasdaq Châtillon, France, 6 octobre 2025 DBV Technologies annonce un placement d’ADS pour un montant d’environ 30 millions de Dollars US dans le cadre de son programme At-The-Market (ATM) sur le Nasdaq DBV Technologies (la « Société » ou « DBV ») (Euronext : DBV - ISIN : FR0010417345 - Nasdaq Capital Market : DBVT), société biopharmaceutique en phase clinique, annonce ce jour, dans le cadre de son programme de financement dit « At-The-Ma...
Ipsos: 1 director
A director at Ipsos bought 500 shares at 37.238EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Cl...
Ipsos: Monthly declaration of shares and voting rights - August 2025
Ipsos: Monthly declaration of shares and voting rights - August 2025 September 26, 2025 MONTHLY DISCLOSURE OF THE TOTAL NUMBER OF SHARES AND VOTING RIGHTS Articles L. 233-8 II of the Commercial Code and 223-16 of the General Regulation of the AMF Date Shares Voting rights Theoretical* Exercisable** 31 August 2025 43,203,225 48,980,673 48,926,276 *This number is calculated on the basis of all the shares to which voting rights are attached, including shares which voting rights have been suspended, in accordance with Article 223-11 of the AMF general regulation re...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.